AU6502699A - Delivery of phosphoinositide polyphosphates into cells - Google Patents

Delivery of phosphoinositide polyphosphates into cells Download PDF

Info

Publication number
AU6502699A
AU6502699A AU65026/99A AU6502699A AU6502699A AU 6502699 A AU6502699 A AU 6502699A AU 65026/99 A AU65026/99 A AU 65026/99A AU 6502699 A AU6502699 A AU 6502699A AU 6502699 A AU6502699 A AU 6502699A
Authority
AU
Australia
Prior art keywords
cell
cells
group
label
nbd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU65026/99A
Other languages
English (en)
Inventor
Daryll B. Dewald
Shoichiro Ozaki
Glenn D. Prestwich
Joseph Shope
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation UURF
Utah State University USU
Original Assignee
University of Utah Research Foundation UURF
Utah State University USU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation UURF, Utah State University USU filed Critical University of Utah Research Foundation UURF
Publication of AU6502699A publication Critical patent/AU6502699A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
AU65026/99A 1998-09-30 1999-09-29 Delivery of phosphoinositide polyphosphates into cells Abandoned AU6502699A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10248298P 1998-09-30 1998-09-30
US60102482 1998-09-30
US39629699A 1999-09-15 1999-09-15
US09396296 1999-09-15
PCT/US1999/022594 WO2000018949A2 (fr) 1998-09-30 1999-09-29 Administration de polyphosphates phosphoinositides dans les cellules

Publications (1)

Publication Number Publication Date
AU6502699A true AU6502699A (en) 2000-04-17

Family

ID=26799415

Family Applications (1)

Application Number Title Priority Date Filing Date
AU65026/99A Abandoned AU6502699A (en) 1998-09-30 1999-09-29 Delivery of phosphoinositide polyphosphates into cells

Country Status (4)

Country Link
EP (1) EP1119315A4 (fr)
AU (1) AU6502699A (fr)
CA (1) CA2345532A1 (fr)
WO (1) WO2000018949A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001265231B2 (en) 2000-05-31 2006-07-06 Promega Corporation Assay for kinases and phosphatases
CN1539021A (zh) 2001-06-11 2004-10-20 Ӧ���о�ϵͳARS�ɷݹ�˾ 氨基糖苷结合分子的新型亲近闪烁检测法
US20050118624A1 (en) * 2003-10-03 2005-06-02 Cumbre Inc. Fluorescent probes for ribosomes and method of use
WO2005063260A2 (fr) * 2003-12-22 2005-07-14 Oregon Health And Science University Procedes et composition pour prevenir des effets secondaires toxiques des medicaments a aminoglycosides
WO2005071095A2 (fr) 2004-01-16 2005-08-04 Applera Corporation Essais fluorogeniques pour kinase et substrats
US7659088B2 (en) * 2006-05-22 2010-02-09 Aureogen Biosciences, Inc. Assay for inositol phosphorylceramide synthase activity
GB0920985D0 (en) * 2009-11-30 2010-01-13 Queen Mary & Westfield College Novel inositol phosphate derivatives
US10350235B2 (en) 2015-08-19 2019-07-16 Joseph Kost Cationic polysaccharides for delivery of phosphoinositides to cells for therapeutic purpose

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1237670A (fr) * 1983-05-26 1988-06-07 Andrew S. Janoff Reduction de la toxicite de certains medicaments

Also Published As

Publication number Publication date
WO2000018949A9 (fr) 2000-08-31
CA2345532A1 (fr) 2000-04-06
WO2000018949A2 (fr) 2000-04-06
EP1119315A2 (fr) 2001-08-01
WO2000018949A3 (fr) 2000-07-20
EP1119315A4 (fr) 2002-04-17

Similar Documents

Publication Publication Date Title
Komine et al. Vacuolar granules in Chlamydomonas reinhardtii: polyphosphate and a 70-kDa polypeptide as major components
Traynor-Kaplan et al. Transient increase in phosphatidylinositol 3, 4-bisphosphate and phosphatidylinositol trisphosphate during activation of human neutrophils
Brownstein et al. Coexistence of Several Putative Neurotransmitters in Single Identified Neurosn of Aplysia
US20090186422A1 (en) Specific inhibitors of nfat activation by calcineurin and their use in treating immune-related diseases
AU6502699A (en) Delivery of phosphoinositide polyphosphates into cells
Siderius et al. CHLAMYDOMONAS EUGAMETOS (CHLOROPHYTA) STORES PHOSPHATE IN POLYPHOSPHATE BODIES TOGETHER WITH CALCIUM 1
Nishizuka Three multifunctional protein kinase systems in transmembrane control
Edwards et al. Ca2+‐dependent phospholipid and arachidonic acid binding by the placental annexins VI and IV
Pap et al. Peptide-based targeting of fluorophores to organelles in living cells
Vivekanandan et al. Evidence for the presence of phosphoinositide cycle and its involvement in cellular signal transduction in the rabbit lens
US7084241B2 (en) Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases
JP2003503423A (ja) キャリア内の生体分子相互作用の取込みおよび適用
Blázquez-Moraleja et al. Shedding light on the mitochondrial matrix through a functional membrane transporter
US6090784A (en) RNA polymerase II peptides and methods of use
Gupta et al. Activation of heart sarcoplasmic reticulum Ca++-stimulated adenosine triphosphatase by insulin.
US11723985B2 (en) Protein delivery to membranes
Cocco et al. Nuclear inositol lipid cycle and differentiation
US20040192601A1 (en) Lipid binding molecules and methods of use
Wirtz Peptide-based target-ing of fluorophores to organelles in living cells.
Yorek et al. Endothelin-stimulated Ca2+ mobilization by 3T3-L1 adipocytes is suppressed by tumor necrosis factor-α
JP2005095178A (ja) 脂質切断酵素
Kawada et al. Inostamycin, an Inhibitor of P‐Glycoprotein Function, Interacts Specifically with Phosphatidylethanolamine
Sabbatini Rat liver nuclear envelope insulin binding and its effects on endogenous protein kinases
CN116097101A (zh) 用于测量生物活性化合物对心磷脂的结合亲和力的测定法
VAN PARIDON et al. Phosphatidylinositol-transfer protein and cellular phosphatidylinositol metabolism

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period